Abstract
The experimental anticancer drug cyclopentenyl cytosine (CPEC) was associated with cardiotoxicity in a phase I study. The aim of the present study was twofold; first we investigated whether the observed effects could be reproduced in in-vitro and in-vivo rat models. Second, we intended to investigate the underlying mechanism of the possible cardiotoxicity of CPEC. Effects on frequency and contractility were studied on the isolated atria of 18 male Wistar rats. Atria were incubated with 0.1 mmol L−1 (n=6) or 1 mmol L−1 (n=6) CPEC for 1.5 h and compared with control atria (incubation with buffer solution, n=6). The cardiac apoptosis-inducing potential was studied in-vivo on 66 rats by 99mTc-Annexin V scintigraphy, followed by postmortem determination of radioactivity in tissues, histological confirmation with the TUNEL assay (late-phase apoptosis), and immunohistochemical staining for cleaved caspase 3 and cytochrome C (early-phase apoptosis). Serum levels of the necrotic cardiomyopathy marker troponin T were also determined. No effect on heart frequency was found in the isolated atria after CPEC treatment. A trend towards a decrease of contraction force was observed. However, the differences were not statistically significant. 99mTc-Annexin V scintigraphy showed no increase in cardiac uptake ratio upon CPEC treatment in the in-vivo rat model, which was confirmed by determination of radioactivity in heart versus blood ratios. At each section a few individual isolated late apoptotic cells (<5) could be identified by the TUNEL assay in the highest CPEC dose group (90 mg kg−1) but not in controls or in rats treated with 60 mg kg−1 CPEC. Staining for the early apoptosis markers cleaved caspase 3 and cytochrome C did not reveal any significant differences between treated and control rats. Cardiac troponin T levels were not increased after CPEC treatment. CPEC does not affect heart frequency or contraction force in our cardiotoxicity models. Moreover, we did not find an indication of CPEC-induced apoptosis in heart tissue.
Similar content being viewed by others
References
Abrams MJ, Juweid M, tenKate CI, Schwartz DA, Hauser MM, Gaul FE, Fuccello AJ, Rubin RH, Strauss HW, Fischman AJ (1990) Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 31:2022–2028
Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki L (2000) Acute doxorubicin cardiotoxicity involves cardiomyocite apoptosis. Cancer Res 60:1789–1792
Bennink RJ, Hoff MJ van den, Hemert FJ van, Bruin KM de, Spijkerboer AL, Vanderheyden JL, Steinmetz N, Eck-Smit BL van (2004) Annexin-V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. J Nucl Med 45:842–848
Blaney SM, Balis FM, Grem J, Cole DE, Adamson PC, Poplack DG (1992) Modulation of the cytotoxic effect of cyclopentenylcytosine by its primary metabolite, cyclopentenyluridine. Cancer Res 52:3503–3505
Blankenberg FG, Strauss HW (1999b) Non-invasive diagnosis of acute heart- or lung-transplantation rejection using radiolabeled annexin V. Pediatr Radiol 29:299–305
Blankenberg FG, Katsikis PD, Tait JF Davis E, Naumovski L, Ohtsuki K, Kopiwoda S, Abrams MJ, Darkes M, Robbins RC, Maecker HT, Strauss HW (1998) In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA 95:6349–6354
Blankenberg FG, Katsikis PD, Tait JF, Davis E, Naumovski L, Ohtsuki K, Kopiwoda S, Abram MJ, Strauss HW (1999a). Imaging of apoptosis (programmed cell death) with 99mTc Annexin V. J Nucl Med 40:184–191
Chandrashekhar Y, Narula J (2003) Death hath a thousand doors to let out life. Circ Res 92:710–714
Ford H, Cooney DA, Ahluwalia GS, Hao Z, Rommel ME, Hicks L, Dobyns KA, Tomaszewski JE, Johns DG (1991) Cellular pharmacology of cyclopentenyl cytosine in molt-4 lymphoblasts. Cancer Res 51:3733–3740
Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493–501
Guchelaar HJ, Vermes A, Vermes I, Haanen C (1997) Apoptosis: molecular mechanisms and implications for cancer chemotherapy. Pharm World Sci 19:119–125
Guchelaar HJ, Vermes I, Koopmans RP, Reutelingperger CH (1998) Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. Cancer Chemother Pharmacol 42:77–83
Habraken JBA, Bruin KM de, Shehata M, Booij J, Bennink RJ, Eck-Smit BLF van, Busemann-Sokole E (2001) Evaluation of high-resolution pinhole SPECT using a small rotating animal. J Nucl Med 42:1863–1869
Heerde WL van, Robert-Offerman S, Dumont E, Hofstra L, Doevendans PA, Smits JFM, Daemen MJAP, Reutelingsperger CPM (2000) Markers of apoptosis in cardiovascular tissues: focus on Annexin V. Cardiov Res 45:549–559
Kostin S, Pool L, Elsässer A, Hein S, Drexler HCA, Arnon E, Hayakawa Y, Zimmermann R, Bauer E, Klövekorn WP, Schaper J (2003) Myocytes die by multiple mechanisms in failing human hearts. Circ Res 92:715–724
Kotamraju S, Konorev EA, Joseph J, Kalylanaraman (2000) Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. J Biol Chem 43:33585–33592
Meinardi MT, Gietema JA, Veldhuisen DJ van, Graaf WT van der, Vries EGE, Sleijfer DT (2000) Long-term chemotherapy-related cardiovascular morbidity. Cancer Treat Rev 26:429–447
O’Brien PJ, Dameron GW, Beck ML, Kang YJ, Erickson BK, Battista THD, Miller KE, Jackson KN, Mittelstadt S (1997) Cardiac Troponin T is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab Anim Sc 47:486–495
Ohtsuki K, Akashi K, Aoka Y, Blankenberg FG, Kopiwoda S, Tait J, Strauss W (1999) Technetium-99 m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis. Eur J Nucl Med 26:1251–1258
Politi PM, Xie F, Dahut W, Ford H, Kelley JA, Bastian A, Setser A, Allegra CJ, Chen AP, Hamilton JM, Arbuck SF, Linz P, Brammer H, Grem JL (1995) Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Cancer Chemother Pharmacol 36:513–523
Sawyer DB, Fukazawa R, Arstall MA, Kelly RA (1999) Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 84:257–265
Schimmel KJM, Richel DJ, Brink RBA van den, Guchelaar HJ (2004) Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 30:181–191
Sternberger LA, Sternberger NH (1986) The unlabeled antibody method. Comparison of peroxidase–antiperoxidase with avidin–biotin complex by a new method of quantification. J Histochem Cytochem 34:599–605
Tait JF, Smith C (1991) Site-specific mutagenesis of annexin V: role of residues from Arg-200 to Lys-207 in phospholipid binding. Arch Biochem Biophys 288:141–144
Verschuur AC, Gennip AH van, Leen R, Meinsma R, Voûte PA, Kuilenburg ABP (2000) In vitro inhibition of cytidine triphosphate synthetase activity by cyclopentenyl cytosine in paediatric acute lymphocytic leukaemia. Br J Haematol 110:161–169
Verschuur AC, Brinkman J, Gennip AH van, Leen R, Vet R, Evers L, Voute PA, Kuilenburg ABP (2001) Cyclopentenyl cytosine induces apoptosis and increases cytarabine induced apoptosis in a T-Lymphoblastic leukemic cell-line. Leuk Res 25:891–900
Viaro F, Dalio MB, Evora PRB (2002) Catastrophic cardiovascular adverse reactions to protamine are nitric oxide/cyclic guanosine monophosphate dependent and endothelium mediated. Chest 122:1061–1066
Acknowledgements
Dr M van den Hoff is financially supported by The Netherlands Heart Foundation (grant M96.003). The animal studies were performed after approval of the Ethical Animal Research Committee of the University of Amsterdam and following its guidelines.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schimmel, K., Bennink, R., de Bruin, K. et al. Absence of cardiotoxicity of the experimental cytotoxic drug cyclopentenyl cytosine (CPEC) in rats. Arch Toxicol 79, 268–276 (2005). https://doi.org/10.1007/s00204-004-0633-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-004-0633-5